Corcept Therapeutics | CORT

Corcept Therapeutics traded at $24.20 this Tuesday June 28th, decreasing $0.91 or 3.61 percent since the previous trading session. Looking back, over the last four weeks, Corcept Therapeutics lost 16.10 percent. Over the last 12 months, its price rose by 8.79 percent. Looking ahead, we forecast Corcept Therapeutics to be priced at 23.16 by the end of this quarter and at 21.34 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
24.20
Daily Change
-3.61%
Yearly
8.79%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Acadia Pharmaceuticals 13.96 -0.68 -4.64% -42.15%
Aurora Cannabis Inc 1.89 -0.12 -5.97% -83.24%
ANI Pharmaceuticals 29.21 -0.97 -3.21% -11.83%
Ardelyx 0.58 -0.03 -4.46% -92.59%
BioMarin Pharmaceutical 82.77 -2.32 -2.73% -0.83%
Bristol-Myers Squibb 78.66 -1.32 -1.65% 18.70%
Corcept Therapeutics 24.20 -0.91 -3.61% 8.79%
Depomed 2.91 0.02 0.52% 79.32%
Esperion Therapeutics 6.34 -0.21 -3.21% -70.00%
Knight Therapeutics Inc 5.36 0.03 0.56% 2.10%
J&J 177.03 -5.09 -2.79% 7.93%
Lannett 0.61 -0.004 -0.62% -87.16%
Eli Lilly 317.63 -9.64 -2.95% 38.48%
Lexicon Pharmaceuticals 2.18 -0.01 -0.46% -56.40%
Merck & Co 91.99 -2.42 -2.56% 19.14%
Nektar Therapeutics 3.95 -0.25 -5.95% -77.31%
Novartis 81.14 -0.90 -1.10% -4.06%
Novartis 84.23 -1.05 -1.23% -8.28%
Omeros 2.85 -0.33 -10.38% -81.09%
Pacira 56.54 -0.67 -1.17% -6.82%
Pfizer 50.61 -1.27 -2.45% 29.44%
Supernus Pharmaceuticals 28.30 -0.69 -2.38% -10.53%
TG Therapeutics 4.01 -0.34 -7.72% -89.35%
Canopy Growth Corp 4.61 -0.28 -5.73% -84.68%
Ziopharm Oncology 1.22 0.12 10.91% -54.48%

Indexes Price Day Year
USND 11214 -310.43 -2.69% -22.81%
US2000 1740 -31.53 -1.78% -24.63%

Corcept Therapeutics
Corcept Therapeutics Incorporated is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the steroid hormone cortisol. The Company has marketed the cortisol modulator Korlym in the United States for the treatment of patients with a form of hypercortisolism known as endogenous Cushing’s syndrome. Cortisol activity can be modulated effectively by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s active ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its portfolio of selective cortisol modulators consists of four structurally distinct series, including relacorilant, exicorilant and miricorilant. These compounds bind to GR but not the progesterone, estrogen or androgen receptors.